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1 |  INTRODUCTION
Diffuse cutaneous mastocytosis (DCM) is a rare and 
potentially fatal form of cutaneous mastocytosis that is 
associated with significant mast cell (MC) infiltration of 
the skin.1-3 As most cutaneous mastocytosis cases are not 
associated with significant morbidity or mortality, it is 
under- recognized that the DCM type of cutaneous masto-
cytosis is associated with fatal complications.1,4 DCM is 
characterized by diffuse dense infiltrates of MCs in the 
dermis, and this high MC burden can result in significant 
amounts of MC mediator release leading to systemic reac-
tions that can be severe and even fatal.5-8 Given the risk for 
life-threatening complications, it is important to consider 
Received: 9 February 2018 | Revised: 22 April 2018 | Accepted: 30 April 2018
DOI: 10.1002/ccr3.1607
C A S E  R E P O R T
Diffuse cutaneous mastocytosis with novel somatic KIT mutation 
K509I and association with tuberous sclerosis
Iris M. Otani1  | Ryan W. Carroll2 | Phoebe Yager2 | Daniela Kroshinsky3 |  
Sarah Murphy2 | Jason L. Hornick4 | Cem Akin5,6 | Mariana Castells5,6 |  
Jolan E. Walter7,8
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
1Division of Pulmonary, Critical Care, 
Allergy, and Sleep Medicine, UCSF 
Medical Center, San Francisco, CA, USA
2Division of Pediatric Critical 
Care Medicine, Department of 
Pediatrics, MassGeneral Hospital for 
Children, Boston, MA, USA
3Department of Dermatology, 
Massachusetts General Hospital, 
MassGeneral Hospital for Children, Boston, 
MA, USA
4Department of Pathology, Brigham and 
Women’s Hospital, Boston, MA, USA
5Mastocytosis Center, Brigham and 
Women’s Hospital, Boston, MA, USA
6Division of Rheumatology, Immunology 
and Allergy, Brigham and Women’s 
Hospital, Boston, MA, USA
7Pediatric Allergy & Immunology, 
Massachusetts General Hospital, Boston, 
MA, USA
8Center for Immunology and Inflammatory 
Diseases, Massachusetts General Hospital, 
Boston, MA, USA
Correspondence
Iris M. Otani, UCSF Medical Center, San 
Francisco, CA, USA.
Email: Iris.Otani@ucsf.edu
Key Clinical Message
Diffuse cutaneous mastocytosis (DCM) is a rare but potentially fatal condition when 
diagnosis and targeted treatments are delayed. This case illustrates the life- threatening 
complications in DCM and reviews the currently available treatments. To our knowl-
edge, this is the first report of mastocytosis with somatic K509I mutation and con-
comitant tuberous sclerosis.
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DCM in pediatric patients with a concerning skin examina-
tion (skin with “peau d’orange” appearance, hyper-pigmen-
tation, positive Darier’s sign). A serum tryptase level is an 
objective screening tool for MC disorders. Early diagnosis 
can allow physicians and patients to avoid MC degranula-
tion triggers and initiate prophylactic therapy to decrease 
the risk of MC activation, minimizing complications and 
improving clinical outcomes.
This case illustrates the clinical course and potentially 
fatal complications of DCM, and the effective treatment 
options that are currently available. This particular case 
is also novel in that it is, to our knowledge, the first re-
ported case of a somatic K509I KIT  mutation and the first 
reported case of concomitant mastocytosis and tuberous 
sclerosis.
2 |  CASE
A four- month- old male infant was referred to an emergency 
department from his pediatrician’s office with fever, irrita-
bility, and bullous skin lesions covering a third of the body 
surface area without mucosal involvement. In the emergency 
department, he decompensated acutely and developed cardiac 
arrest requiring cardiopulmonary resuscitation and hemody-
namic support with dobutamine, dopamine, milrinone, and 
norepinephrine. He required mechanical ventilation for acute 
respiratory distress syndrome and right ventricular heart fail-
ure with evidence of pulmonary hypertension, and emergent 
hemodialysis for acute kidney failure. Due to continued con-
cerns for disseminated infection, he received vancomycin, 
ceftriaxone, acyclovir, and clindamycin. He developed dis-
seminated intravascular coagulopathy and received multiple 
transfusions of packed red blood cells, fresh frozen plasma, 
and cryoprecipitate.
3 |  INITIAL INVESTIGATIONS
While the differential of bullous skin diseases in an infant is 
broad, key clinical findings that pointed to consideration of 
mastocytosis were as follows. The infant’s skin had a yel-
lowish tinge consistent with the “peau d’orange” skin ob-
served in DCM due to heavy MC infiltration (Figure 2C).1 
Manipulation of his skin resulted in erythema and hive, indic-
ative of “Darier’s Sign” observed in mastocytosis patients.1 
The patient had been taking increasing doses of famotidine 
for fussiness attributed to reflux since 2 weeks of age, and 
2 weeks prior to his initial presentation, he developed wors-
ening fussiness and nonbloody loose stools. These gastro-
intestinal symptoms likely reflected activation of mast cells 
normally present in the gut mucosal lining, rather than benign 
reflux and diarrhea.
Skin biopsy of one of the abdominal bullae showed dense 
dermal infiltrate of MCs with subepidermal vesiculation 
consistent with a diagnosis of mastocytosis (Figure 1A). 
Immunohistochemistry for KIT (CD117) showed diffuse 
positivity of the dermal infiltrate, further supporting the 
diagnosis (Figure 1B). Direct immunofluorescence was 
negative for fibrinogen, C3, and immunoglobulins G, M, 
and A.
4 |  TREATMENT
The patient was transferred to our institution for further 
care. He remained critically ill in the pediatric intensive 
care unit for a total of 31 days. Initial skin examination 
showed diffuse blisters and bullae containing serous fluid 
over the chest, abdomen, back, neck, and posterior scalp 
(Figure 2A). A total serum tryptase level were 162 nano-
grams/milliliter (ng/mL), (normal range <11.4 ng/mL). 
Mature β- tryptase was <1 ng/mL (normal range <1 ng/
mL). Significance of these laboratory results discussed 
below.
Treatment was initiated with systemic steroids (methyl-
prednisolone 6.3 milligrams (mg) intravenously (IV) every 
6 hours), H1- antihistamine and H2- antihistamines (diphen-
hydramine 6.25 mg IV every 6 hours and famotidine 3 mg 
IV every 24 hours), leukotriene antagonist (montelukast 
4 mg per nasogastric tube every 24 hours), proton pump 
inhibitor (esomeprazole 3 mg IV every 12 hours), and MC 
stabilizer (cromolyn sodium enteral concentrate 30 mg per 
nasogastric tube every 6 hours). Precautions were taken to 
avoid MC degranulation triggers: physical stimuli—fric-
tion of skin lesions, heat, cold, pressure, and drugs with 
MC degranulation potential including vancomycin and ra-
diocontrast media.9-11
5 |  FURTHER INVESTIGATIONS 
AND FINAL DIAGNOSIS
Further investigations were performed to investigate the ex-
tent of MC involvement. Bone marrow (BM) aspirate smears 
showed normal MC numbers with normal MC morphology 
without aberrant CD25+ MCs. BM flow cytometry did not 
show any evidence of abnormal CD117+/CD25+ MCs. 
The percentage of CD25+/CD117dim+/CD2dim+/CD3(- )/
CD34(- ) BM MCs detected by flow cytometry was 0.03%. 
Gastrointestinal (GI) biopsies of the esophagus, stomach an-
trum, and duodenum did not show increased MC numbers or 
abnormal MC morphology. The absence of systemic involve-
ment on available BM and GI studies supported a diagnosis 
of cutaneous mastocytosis, subtype diffuse cutaneous masto-
cytosis (DCM).
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KIT (tyrosine kinase) mutational analysis performed 
to guide cytoreductive therapy options with tyrosine ki-
nase inhibitors was positive for K509I mutation on skin 
biopsy and peripheral blood at a level consistent with a so-
matic mutation (~10%). KIT mutational analysis was per-
formed by extracting DNA from bone marrow aspirate and 
paraffin- embedded skin tissue and screened for mutations 
by Sanger sequencing and high- resolution melting curve 
analysis.
Patient has been stable on follow- up to date 3 years after 
initial presentation with DCM management. However, as the 
K509I mutation is also associated with well- differentiated 
systemic mastocytosis, if patient develops new symptoms in 
the future, BM core biopsy may be needed to definitively rule 
out well- differentiated systemic mastocytosis.12
Further studies were also performed to investigate the 
subtle clinical seizures that started during hospitalization. 
Electroencephalography showed evidence of status epilep-
ticus, and brain MRI/MRA showed findings suggestive of 
hypoperfusion and excitotoxic injury with the additional inci-
dental detection of subependymal nodules and cortical tubers 
concerning for TS complex. Genetic sequencing revealed a 
heterozygous c.3397 + 5 G>A splice site mutation in the 
TSC2 gene, supporting a diagnosis of TS.
6 |  OUTCOME AND FOLLOW- UP
With continuation of the above treatment and cautious 
avoidance of MC triggers, total serum tryptase levels 
decreased (Figure 3) and skin continued to improve, with re- 
epithelialization and only scattered small focal erosions at sites 
of previous bullae remaining 2 weeks after admission to our 
institution (Figure 2B). Imatinib was considered but deferred 
given improvement with the above treatment. At time of retro- 
transfer to the referring hospital 1 month after presentation, 
neurologic examination was notable for an awake, alert in-
fant with development of spasticity in all extremities, and the 
dermatologic examination was notable for re- epithelialization 
and slightly thickened skin with a yellowish hue (Figure 2C).
7 |  DISCUSSION
Diffuse cutaneous mastocytosis is a form of cutaneous masto-
cytosis that typically presents with cutaneous manifestations 
at birth or early infancy.2,13 DCM arises from a clonal MC 
expansion and is often due to a gain- of- function mutation in 
KIT, which encodes the receptor for stem cell factor (SCF), 
a potent MC growth factor.2,13 Degranulation of cutaneous 
MCs release MC mediators into the systemic circulation and 
cause systemic symptoms.6,14-16
Skin examination is key to differentiate DCM from 
other benign forms of cutaneous mastocytosis and other 
bullous dermatological conditions. In DCM, the skin can 
develop a thickened, leathery appearance with yellow-
ish discoloration, accentuation of hair follicles, and in-
creased folding (“peau d’orange”).14 Blistering, flushing, 
erythema, edema, pruritus, and dermatographism can 
also be seen.14 Darier’s sign, elicited by gently stroking 
F I G U R E  1  A, Skin biopsy of 
an abdominal bulla showed a dense 
dermal infiltrate of mast cells with 
subepidermal vesiculation consistent with 
a diagnosis of bullous mastocytosis. B, 
Immunohistochemistry for KIT (CD117) 
showed diffuse positive staining of the 
dermal infiltrate consistent with cutaneous 
mastocytosis
(A) 
(B) 
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F I G U R E  3  Tryptase levels during 
hospitalization Hospital Day
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F I G U R E  2  A, Day 1 at our 
institution. Multiple tense vesicles and 
bullae filled with serous or hemorrhagic 
fluid and few large flaccid bullae over 
the abdomen. Multiple clean- based large 
erosions over the back. B, Day 5 at our 
institution. Chest and abdomen with near 
complete reattached epidermis, back with 
healing clean- based erosions in various 
stages of re- epithelialization. C, Day of 
transfer from our institution back to outside 
hospital near parents’ home (day 31 at our 
institution). Erythematous patches at sites of 
healed lesions over the torso
(A) 
(B) 
(C) 
1838 |   OTANI eT Al.
the affected skin, is often demonstrated.14,17 Darier’s 
sign, although an important screening tool for masto-
cytosis, should not be elicited in children with cutane-
ous mastocytosis presenting with extensive cutaneous 
involvement. This is because skin manipulation in this 
situation can trigger life- threatening massive mast cell 
mediator release associated with extensive cutaneous 
involvement.7,10
A total serum tryptase level is a simple and effective 
test to screen for mast cell disorders. An elevated total 
serum tryptase level indicates an aberration in MC func-
tion and/or number and should prompt an urgent referral 
to an allergist.6,10 Total tryptase levels can be elevated due 
to elevations of the inactive protryptase form or the active 
β- tryptase form.18 Measuring a β- tryptase level identifies 
which form is elevated. A normal β- tryptase level equates 
to elevation of inactive protryptase and a baseline higher 
MC burdern.6,10 An elevated β- tryptase level indicates 
that MCs were recently activated and released β- tryptase 
(the half- life of tryptase is on the order of two to four 
hours).18
Our patient had an elevated total serum tryptase level 
and a normal β- tryptase level. Most likely, the β- tryptase 
level would have been elevated if it was checked in the two 
to four hours after presentation (it was checked more than 
24 hours after the initial presentation). Acute elevation of 
beta- tryptase is a risk factor for developing DIC, which oc-
curred in our patient, as active beta- tryptase can cleave fi-
brinogen to fibrin.19 The normal β- tryptase level meant that 
the total serum tryptase level consisted of predominantly 
inactive protryptase reflecting an increased risk for severe 
MC activation.6,10
Serum tryptase is also one of the key factors that can 
help identify children with cutaneous mastocytosis at risk 
for fatal or near- fatal mast cell activation events. Previous 
reports of fatal bullous mastocytosis cases suggest that neo-
natal onset of cutaneous lesions,20 extensive bullous cuta-
neous involvement,7,15 and symptoms of vasodilation and 
flushing7 are common clinical factors associated with fatal 
mast cell activation events. An analysis of 111 children with 
cutaneous mastocytosis found that extensive cutaneous dis-
ease involving >90% of body surface area and serum tryptase 
>15.5 μg/L are associated with severe symptoms requiring 
hospitalization.10 The same study found that serum tryptase 
>30.8 μg/L is associated with severe symptoms requiring 
management in an ICU.10
Early consideration of DCM prompting allergy refer-
ral is crucial as early diagnosis allows for avoidance of 
MC triggers that lead to potentially fatal MC activation. 
Patients with DCM are particularly prone to MC triggers 
due to skin manipulation, as perivascular MC infiltrates 
are present even in areas of skin that appear normal on 
the surface.3,16 Even precipitous temperature changes and 
routine vaccination can cause severe generalized blister-
ing.16,21 Therefore, patients are likely to suffer severe re-
actions in response to MC triggers ubiquitous in daily life 
unless they are educated regarding conscious avoidance of 
MC triggers.
In addition to avoidance of MC triggers, early diagnosis 
allows for initiation of effective prophylaxis. Prophylactic 
therapy with long- acting antihistamines is the mainstay of 
treatment.16,22 Cromolyn sodium, a MC stabilizer, can be 
administered via an enteral route to treat gastrointestinal 
symptoms.23 Leukotriene antagonists can be efficacious in 
bullous mastocytosis.24 Glucocorticoids can be used in severe 
cases.5,25 Symptom remission has been reported for 2 months 
to years after PUVA (psoralen, which makes the skin more 
sensitive to UV light, and ultraviolet A) therapy.26-28
Furthermore, preceding awareness of a DCM diagnosis 
can improve treatment in cases where patients experience 
a life- threatening flare despite MC trigger avoidance and 
prophylactic therapies. Epinephrine is the vasopressor of 
choice when these patients develop cardiovascular collapse, 
as it can stabilize MCs and prevent further degranulation.2 
Medications with known MC degranulation potential (in-
cluding vancomycin and general anesthetics and radiocon-
trast media) should only be used after careful consideration 
and discussion with an allergy specialist.2,16
This case also has unique genetic features. To the best of 
our knowledge, our case is the first report of a somatic K509I 
KIT mutation. The majority of KIT mutations are somatic,2 
with D816V (valine for aspartate in codon 816 [exon 17], 
Asp816Val) being the most commonly seen KIT mutation 
in mastocytosis.29 There have been three reports of familial 
mastocytosis due to germline but not somatic K509I muta-
tion and one report of an individual with a de novo germline 
mutation.12,30-32
In addition to the somatic K509I KIT mutation, our pa-
tient had a mutation in the TSC2 gene. The TS complex 
causes benign solid organ tumors and is not known to affect 
immune cells (including mast cells).33 Although our patient 
had a specific mutation that accounted for the MC clonality 
causing his DCM, it is interesting to note in the context of 
our patient’s particularly severe and life- threatening initial 
presentation that the TSC1 and TSC2 protein- complex is 
a tumor suppressor and that mastocytosis (cutaneous and 
systemic) is a clonal disorder of mast cells.3,33 Literature 
review did not reveal other published reports describing a 
link between TS and mastocytosis and possible associa-
tions between this KIT mutation and TSC2 mutation remain 
conjecture.
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